Clinical trial No longer in our active list Phase 4 Interventional Ages 18 and up

Using Exparel injection to manage postoperative eye pain

Official title: Postoperative Pain Control After Enucleation or Evisceration, a Double-Masked Randomized Controlled Trial of Standard Versus Slow-release Bupivacaine

Run by Mayo Clinic · NCT02381353 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing if an injection called Exparel can help reduce pain after eye removal surgeries for patients compared to regular pain relief options.

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment88 (estimated)
SponsorMayo Clinic
Academic / other
Locations2 sites (Ann Arbor, Michigan and 1 other locations)
Trial IDNCT02381353 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults undergoing enucleation or evisceration of the eye at the participating institutions.

Probably not a fit

Patients under 18 years old, pregnant, or nursing will not benefit from this study as Exparel has not been tested in these populations.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of Exparel, a liposomal formulation of bupivacaine, in managing postoperative pain following eye removal surgeries such as enucleation and evisceration. The study aims to assess pain levels, opioid usage, and patient satisfaction in individuals receiving Exparel compared to standard bupivacaine injections. Participants will be monitored for pain control over a period of several days post-surgery. The trial is conducted at the Mayo Clinic and the University of Michigan Kellogg Eye Institute.

Why it matters

Potential benefit: If successful, this approach could significantly reduce postoperative pain and opioid consumption for patients undergoing eye removal surgeries.

How similar studies have gone: Previous studies have shown success with Exparel in various surgical settings, indicating potential for effective pain management in this novel application.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion criteria:

1. All patients undergoing enucleation or evisceration of the eye whose surgery is performed by the Department of Ophthalmology at Mayo Clinic Rochester
2. Willing and able to comprehend a numerical rating scale system and provide a score to assess pain, nausea, and satisfaction level.

Exclusion criteria:

1. Age less than 18 years (Exparel has not been tested in a pediatric population)
2. Pregnant or nursing (Exparel has not been tested in this patient population)

Where it's running

  • Mayo Clinic in Rochester
    Rochester, Minnesota, United States
    Recruiting
  • University of Michigan Kellogg Eye Institute
    Ann Arbor, Michigan, United States
    Completed

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.